relapsed

Related by string. relapsing * * relapsing remitting multiple sclerosis . relapsed multiple myeloma . relapsed refractory multiple myeloma . relapsed refractory AML . relapsed ovarian cancer . relapsed AML . relapsing remitting MS . relapsing forms . relapsing remitting . relapsed refractory . relapsing MS . relapsing multiple sclerosis . chronic relapsing . relapsed refractory aggressive *

Related by context. All words. (Click for frequent words.) 68 relapse 63 relapsed refractory 62 relapsing 61 refractory CTCL 60 refractory myeloma 60 chemotherapy regimen 60 refractory AML 60 refractory NSCLC 59 chemotherapy regimens 58 refractory HL 58 leukemia APL 58 follicular NHL 58 leukemia CLL 58 heavily pretreated 58 leukemia AML 57 remission induction 57 dasatinib 57 refractory multiple myeloma 57 relapsed refractory multiple myeloma 57 refractory indolent NHL 57 heavily pretreated patients 57 monotherapy 57 refractory indolent non 56 remission 56 refractory SCLC 56 refractory Hodgkin lymphoma 56 indolent NHL 56 CHOP chemotherapy 56 chemotherapy 56 refractory acute myeloid 56 HER2 positive metastatic breast 56 refractory PTCL 55 temozolomide 55 refractory systemic ALCL 55 metastatic renal cell carcinoma 55 docetaxel chemotherapy 55 lymphoma CTCL 55 prior chemotherapy regimens 55 refractory cutaneous T 55 rituximab 55 relapses 55 FOLFIRI 55 IV metastatic melanoma 54 acute myelogenous leukemia AML 54 refractory CLL 54 carboplatin 54 dose cohorts 54 cell lymphoma CTCL 54 chronic myeloid leukemia CML 54 chronic lymphocytic leukemia CLL 54 chlorambucil 54 Hodgkin lymphoma NHL 54 imatinib 54 non metastatic osteosarcoma 54 systemic ALCL 54 leukemia ALL 54 previously untreated follicular 54 docetaxel 54 metastatic colorectal cancer 54 bendamustine 54 gastrointestinal stromal tumor GIST 54 non Hodgkin lymphoma 53 diagnosed multiple myeloma 53 mRCC 53 fludarabine 53 relapsed multiple myeloma 53 acute myeloid leukemia 53 glufosfamide 53 refractory ALCL 53 rituximab refractory 53 plus ribavirin 53 imatinib therapy 53 sunitinib 53 mCRC patients 53 disease modifying antirheumatic 53 erlotinib 53 evaluable patients 53 unresectable 53 azathioprine 53 vandetanib 53 platinum refractory 53 HCV infected 53 DMARD 53 EGFR expressing mCRC 53 refractory 53 resistant ovarian cancer 53 azacitidine 53 systemic anaplastic large 53 refractory DLBCL 53 refractory follicular 53 NSCLC 53 superficial bladder cancer 52 myelofibrosis 52 bipolar depression 52 advanced NSCLC 52 relapsing remitting multiple sclerosis 52 Relapsed 52 follicular lymphoma 52 bortezomib 52 ribavirin therapy 52 non Hodgkin Lymphoma 52 gemcitabine 52 infliximab 52 hormone refractory prostate cancer 52 castration resistant prostate cancer 52 Non Hodgkin Lymphoma 52 dasatinib Sprycel ® 52 DMARD therapy 52 relapsers 52 metastatic SCCHN 52 diagnosed glioblastoma multiforme 52 imatinib Gleevec ® 52 pegylated interferon 52 nab paclitaxel 52 relapsing remitting MS 52 evaluable 51 nilotinib 51 primary hypercholesterolemia 51 recurrent GBM 51 metastatic malignant melanoma 51 achieve sustained virologic 51 CVP chemotherapy 51 diagnosed Ph + 51 phase Ib 51 CML CP 51 multiple myeloma 51 metastatic NSCLC 51 anthracycline taxane 51 lenalidomide Revlimid R 51 bevacizumab 51 amrubicin 51 refractory chronic lymphocytic 51 refractory follicular lymphoma 51 chemotherapy docetaxel 51 pemetrexed 51 vinorelbine 51 taxane chemotherapy 51 5-FU/LV 51 DMARDs 51 recurrent glioblastoma multiforme 51 irinotecan 51 refractory MCL 51 visilizumab 51 refractory APL 51 metastatic pancreatic cancer 51 ribavirin RBV 51 peginterferon 51 Hodgkin lymphoma 51 sorafenib 51 metastatic melanoma 51 neoadjuvant chemotherapy 51 leukemia CML 51 IMGN# 51 refractory chronic myeloid 51 myelodysplastic syndrome MDS 51 indolent lymphoma 51 Xcytrin 50 CVP cyclophosphamide vincristine 50 chronic myeloid leukemia 50 HAART 50 refractory diffuse 50 FOLFOX 50 stage IIIB 50 metastatic malignant 50 Fludara 50 irinotecan containing 50 CHOP cyclophosphamide doxorubicin vincristine 50 virologic failure 50 relapsed MM 50 lupus nephritis 50 RECIST criteria 50 lymphoid blast 50 rALLy 50 Fludarabine 50 irinotecan chemotherapy 50 DLBCL 50 chemoradiation 50 plus dexamethasone 50 T#I mutation 50 imatinib resistant 50 free survival PFS 50 Ph + ALL 50 VELCADE melphalan 50 relapsed CLL 50 gefitinib 50 PREZISTA r 50 chemo radiotherapy 50 MabCampath 50 mapatumumab 50 refractory rituximab naive 50 pixantrone 50 prostate cancer HRPC 50 partial remissions 50 pomalidomide 50 macroglobulinemia 50 undetectable HCV RNA 50 cytogenetic responses 50 FOLFIRI alone 50 renal cell carcinoma 50 anti leukemic 50 blastic phase 50 anthracycline containing 50 standard chemotherapy regimens 50 eculizumab 50 acute GvHD 50 remitting MS 50 fluorouracil 50 biologic therapy 50 Doxil ® 50 manic episodes 50 relapsed Acute Myeloid 50 achieved ACR# 50 mitoxantrone 50 receptor tyrosine kinase inhibitor 50 interferon ribavirin 50 RRMS patients 49 metastatic RCC 49 metastatic breast cancer 49 dacarbazine 49 HGS ETR1 49 B CLL 49 relapsed refractory ALL 49 dexamethasone 49 virological failure 49 dacarbazine DTIC 49 tumor shrinkage 49 picoplatin 49 gastrointestinal stromal tumors 49 refractory peripheral T 49 interferon therapy 49 detectable HCV RNA 49 Telintra 49 Acute Lymphoblastic Leukemia 49 cytotoxic therapy 49 erlotinib Tarceva ® 49 aHUS 49 relapsed leukemia 49 HBeAg positive 49 Diffuse Large B 49 FOLFOX4 49 Gleevec imatinib 49 HER2 negative 49 lamivudine refractory patients 49 low dose cytarabine 49 refractory CML 49 IV melanoma 49 KRAS mutant tumors 49 metastatic squamous cell carcinoma 49 abiraterone 49 chemo 49 acute myeloid leukemia AML 49 phase IIb clinical 49 Acute Myelogenous Leukemia AML 49 evaluating Xcytrin 49 Annamycin 49 Clolar 49 solid tumors 49 lymphoma 49 CR nPR 49 gefitinib Iressa 49 acute leukemia 49 metastatic CRPC 49 hematologic 49 non Hodgkins Lymphoma 49 mitoxantrone plus 49 symptomatic BPH 49 CCyR 49 refractory acute promyelocytic 49 Amrubicin 49 FOLFOX chemotherapy 49 null responders 49 Telcyta 49 HRPC 49 cetuximab Erbitux R 49 phase Ph + 49 methotrexate MTX 49 Myelodysplastic Syndrome MDS 49 PegIFN RBV 49 dosing cohort 49 Herceptin trastuzumab 49 protease inhibitor PI 49 virologically 49 imatinib Gleevec 49 chronic myelogenous leukemia 49 refractory lymphoma 49 temsirolimus 49 ofatumumab 49 dose escalation phase 49 TMC# [001] 49 idiopathic thrombocytopenic purpura 49 refractory ovarian cancer 49 etoposide 49 sustained virologic response 49 achieved sustained virological 49 Acute Lymphocytic Leukemia 49 antidepressant therapy 48 topotecan 48 forodesine 48 Rituxan rituximab 48 peginterferon alfa 2a 48 relapsed AML 48 alkylating agent 48 rindopepimut 48 carfilzomib 48 mCRC 48 chronic hepatitis C 48 decitabine 48 paclitaxel Taxol R 48 mitoxantrone chemotherapy 48 glioblastoma 48 galiximab 48 recurrent glioblastoma 48 untreated multiple myeloma 48 cutaneous T 48 CLL SLL 48 oral naltrexone 48 perifosine 48 adalimumab 48 Flu Cy 48 tamoxifen therapy 48 cell chronic lymphocytic 48 oral vancomycin 48 prior chemotherapy regimen 48 IV NSCLC 48 PEGINTRON 48 brain metastases 48 neurologic progression 48 Acute Myeloid Leukemia AML 48 Marqibo 48 lumiliximab 48 doxorubicin HCl liposome injection 48 pegylated interferon peg IFN 48 mcg kg 48 cisplatin 48 hepatitis C genotype 48 clofarabine 48 TTF Therapy 48 sorafenib Nexavar ® 48 anthracyclines taxanes 48 EGFR TKI 48 anthracycline 48 relapsed ovarian cancer 48 untreated chronic lymphocytic 48 lamivudine 48 alvespimycin 48 anti TNF 48 histologically confirmed 48 bortezomib refractory 48 tumors GIST 48 HBeAg negative patients 48 induce remission 48 prednisolone chemotherapy 48 dosing cohorts 48 relapsing remitting 48 anti rheumatic 48 naïve HCV 48 depressive episode 48 HCV genotype 1 48 cetuximab 48 baminercept 48 docetaxel Taxotere 48 peginterferon alfa 2b 48 HAART regimen 48 idarubicin 48 alcoholism 48 metastatic renal cell 48 Bezielle 48 cytotoxic chemotherapy 48 dose regimens 48 eribulin 48 chronic myelogenous leukemia CML 48 OADs 48 anthracycline therapy 48 methotrexate therapy 48 fallopian tube carcinoma 48 stage IIIb IV 48 Stage IIIB IV 48 ASCT 48 Cloretazine 48 Phase 2b study 48 operable breast cancer 48 tocilizumab 48 relapsing MS 48 mycophenolate mofetil 48 progression TTP 48 KRAS mutations occur 48 PXD# 48 multiple myeloma MM 48 #mg/m# [002] 48 TNF inhibitor 48 taxane therapy 48 plus prednisone prednisolone 48 AGILECT R 48 cytogenetic response 48 cabazitaxel 48 alfa 2a 48 immune thrombocytopenic purpura ITP 48 cetuximab Erbitux ® 48 PEGINTRON TM 48 abstinent 48 Arzerra ofatumumab 48 cytarabine daunorubicin 48 gastrointestinal stromal tumors GIST 48 trastuzumab 48 pegfilgrastim 48 CLL 48 Glioblastoma Multiforme 48 peg interferon 48 biochemical relapse 48 panitumumab 48 differentiated thyroid 48 delayed onset CINV 48 elacytarabine 48 stage IIIB IV 48 metastatic GIST 48 cutaneous T cell 48 Cytoxan 48 retreatment 48 risperidone olanzapine 48 advanced carcinoid 48 axitinib 48 hypomethylating agents 48 abiraterone acetate 48 cytarabine 48 chemoradiotherapy 48 alkylating agents 47 Bcr Abl T#I mutation 47 pazopanib 47 dose dexamethasone 47 relapsed acute myelogenous 47 refractory Hodgkin 47 relapsed refractory aggressive 47 acute lymphoblastic leukemia 47 APTIVUS r 47 hormonal therapy 47 adriamycin 47 dexamethasone Decadron 47 metastatic prostate cancer 47 Velcade 47 5FU 47 cyclophosphamide 47 subcutaneous methylnaltrexone 47 melphalan 47 interferon alfa 2a 47 thalidomide Thalomid 47 pegylated interferon alfa 2a 47 refractory metastatic colorectal cancer 47 FOLOTYN 47 recurrent NSCLC 47 ponatinib 47 pegylated interferon alpha 47 metastatic kidney 47 acute myelogenous leukemia 47 ascending doses 47 mycophenolate mofetil MMF 47 nalmefene 47 registrational 47 BARACLUDE ® 47 Sprycel dasatinib 47 enzastaurin 47 chronic lymphocytic leukemia 47 adjuvant therapy 47 Adjuvant chemotherapy 47 follicular lymphoma FL 47 Median PFS 47 therapy 47 lymphocytic leukemia 47 nonresponders 47 cancer mCRC 47 antiretroviral naive 47 nilotinib Tasigna ® 47 antidepressant medication 47 quetiapine 47 dose dose escalation 47 achieved sustained virologic 47 methotrexate 47 eosinophilic asthma 47 dose escalation clinical 47 HBeAg positive patients 47 VELCADE 47 Phase 2a trial 47 MCyR 47 cell lymphoma 47 relapsed GBM 47 #mg QD [001] 47 IIIB NSCLC 47 Hodgkin Lymphoma 47 Mylotarg 47 myelodysplastic syndromes 47 MabThera Rituxan 47 Hodgkin lymphoma HL 47 randomized #:# 47 SPRYCEL 47 mg kg dose 47 oxaliplatin 47 stage IIIb 47 randomized Phase 47 gemcitabine chemotherapy 47 HCV SPRINT 47 systemic ALCL patients 47 oral rivaroxaban 47 KRN# 47 5 fluorouracil 47 potentially hepatotoxic 47 Dacogen 47 dasatinib Sprycel 47 TMC# C# 47 bipolar mania 47 Follicular Lymphoma 47 Jevtana 47 complete cytogenetic 47 HER2 positive breast cancer 47 Clofarabine 47 chronic plaque psoriasis 47 relapsed SCLC 47 ritonavir boosted 47 metastatic lung cancer 47 blinatumomab 47 administered orally 47 refractory colorectal cancer 47 follicular non 47 median PFS 47 mg/m2 dose 47 idiopathic thrombocytopenic purpura ITP 47 panobinostat 47 Taxotere ® 47 recurrent malignant glioma 47 tofacitinib 47 octreotide 47 boosted protease inhibitor 47 complete remissions 47 imatinib mesylate 47 recurrent ovarian cancer 47 ER CHOP 47 adjunctive placebo 47 disease progression 47 DOXIL ® 47 Tarceva erlotinib 47 pertuzumab 47 Response Evaluation Criteria 47 Acute Myeloid Leukemia 47 splenectomy 47 Pixantrone 47 carboplatin paclitaxel 47 estramustine 47 EGFR expressing 47 Onrigin 47 lapatinib 47 huN# DM1 47 dirucotide 47 cilengitide 47 liver cancer 47 cisplatin chemotherapy 47 Median survival 47 afatinib 47 platelet transfusions 47 Non Hodgkins Lymphoma 47 AP# [003] 47 depressive episodes 47 Phase 2b clinical 47 Myelodysplastic Syndrome 47 NNRTI 47 lymphoblastic leukemia 47 acute leukemias 47 cirrhotic 47 ixabepilone 47 relapsing remitting MS RRMS 47 rapid virologic response 46 CIMZIA TM 46 ORAL HYCAMTIN 46 capecitabine 46 aripiprazole 46 non hodgkin lymphoma 46 underwent liver transplantation 46 adalimumab Humira 46 sunitinib malate 46 Traficet EN 46 CR CRu 46 cell acute lymphoblastic 46 lenalidomide 46 dosing regimens 46 dose regimen 46 plasma uric acid 46 Acute Myeloid Leukaemia AML 46 advanced epithelial ovarian 46 patients evaluable 46 clozapine 46 Vectibix 46 Folfox 46 HCV RESPOND 2 46 Rituxan 46 adjuvant chemotherapy 46 metastatic CRC 46 Relapsed Refractory 46 substance abuse 46 RG# [001] 46 mercaptopurine 46 antiretroviral regimen 46 venlafaxine XR 46 trastuzumab Herceptin ® 46 myelodysplastic syndromes MDS 46 doublet chemotherapy 46 iniparib 46 untreated AML 46 Rituximab 46 Peg IFN 46 relapsed myeloma 46 relapsed indolent NHL 46 RGT arm 46 non Hodgkin lymphomas 46 Pemetrexed 46 hepatic metastases 46 non metastatic resectable 46 chronic HCV 46 refractory systemic anaplastic 46 weekly subcutaneous injections 46 BRIM3 46 dysthymia 46 valproate 46 Alemtuzumab 46 unresectable stage 46 linezolid 46 nitazoxanide 46 cell carcinoma RCC 46 fallopian tube cancers 46 schizophrenic bipolar 46 CRp 46 pancreatic NET 46 liver metastases 46 metastatic castration resistant 46 virological response 46 natalizumab 46 TACE 46 relapsing multiple sclerosis 46 buprenorphine naloxone 46 Revlimid lenalidomide 46 alefacept 46 CANCIDAS 46 #mg/m# [001] 46 peg IFN 46 acute mania 46 radioimmunotherapeutic agent 46 doxorubicin cyclophosphamide 46 placebo dexamethasone 46 colorectal cancer liver metastases 46 COPAXONE ® 46 bevacizumab Avastin ® 46 PSADT 46 decompensated liver disease 46 Irinotecan 46 bosentan 46 Chronic Myeloid Leukemia 46 cancer recurred 46 advanced metastatic renal 46 telaprevir dosed 46 HCV infection 46 ZEVALIN 46 mg BID 46 darunavir ritonavir 46 mutated KRAS gene 46 TNF inhibitors 46 plus prednisone 46 psychiatric hospitalization 46 atherothrombotic events 46 pegylated liposomal doxorubicin 46 remission CR 46 dirucotide MBP# 46 TNF antagonist 46 efficacy endpoint 46 partial onset seizures 46 metastatic hormone refractory 46 Phase IIa trial 46 treatment 46 colorectal liver metastases 46 lintuzumab 46 progressive PsA 46 tyrosine kinase inhibitors 46 weekly intravenous infusions 46 satraplatin 46 cell lung cancer 46 de novo kidney transplant 46 phase 2a 46 lamotrigine 46 venlafaxine ER 46 pivotal Phase 46 endocrine therapy 46 ovarian carcinoma 46 neoadjuvant 46 non splenectomized 46 glioblastoma multiforme GBM 46 follicular Non Hodgkin 46 HSCT 46 interferon alfa 2b 46 DFMO 46 Waldenstrom macroglobulinemia 46 treatment naive genotype 46 nucleoside naive 46 VIDAZA 46 Phase 2a clinical 46 Gleevec resistant 46 arbaclofen 46 myelofibrosis MF 46 cyclophosphamide doxorubicin vincristine 46 Revlimid 46 trabectedin 46 non myeloid malignancies 46 mastectomy chemotherapy 46 panitumumab Vectibix 46 intravenous belinostat 46 acute lymphoblastic 46 cancer neuroendocrine tumor 46 biliary tract cancer 46 docetaxel prednisone 46 sorafenib Nexavar 46 hepatic encephalopathy HE 46 SPRYCEL ® 46 lymphoid malignancies 46 citalopram 46 KRAS wild 46 XR NTX 46 virus HCV protease inhibitor 46 taxane 46 cell lymphoma PTCL 46 Navelbine ® 46 Pegasys ® 46 refractory Ph + 46 Non Hodgkin lymphoma 46 mg/m2 46 FOLFOX6 46 oral COTI 46 resectable 46 taxane chemotherapy administered 46 Crohn disease 46 Sutent sunitinib 46 FavId 45 everolimus tablets 45 Gleevec imatinib mesylate 45 myeloablative 45 steroid refractory ulcerative 45 mutant KRAS 45 4mg/kg 45 TORISEL 45 basiliximab 45 major depressive disorder 45 oral methylnaltrexone 45 Cutaneous T 45 raltegravir 45 acute gout flares 45 gemcitabine carboplatin 45 transcriptase inhibitor NNRTI 45 desvenlafaxine succinate 45 surrogate endpoint 45 LHRH analogues 45 demonstrated antitumor activity 45 zoledronic acid 45 unresectable locally advanced 45 prodromal symptoms 45 thymoma 45 diagnosed chronic myeloid 45 prostate cancer CRPC 45 VFEND 45 progressive psoriatic arthritis 45 macroalbuminuria 45 chronic myeloid 45 HER2 positive 45 metastatic HRPC 45 refractory gout 45 8mg/kg 45 metastatic sarcoma 45 trastuzumab Herceptin R 45 preoperative chemotherapy 45 vinflunine 45 Acute Myelogenous Leukemia 45 treatment regimens 45 pegylated interferon alfa 45 peginterferon alfa 45 Femara letrozole 45 Cloretazine ® 45 clodronate 45 substance abuser 45 SCCHN 45 ACTEMRA TM 45 infliximab therapy 45 valopicitabine 45 Sutent 45 standard chemotherapy regimen 45 Omacetaxine 45 olaparib 45 investigational compound 45 Sprycel 45 lapatinib Tykerb 45 molindone 45 immune thrombocytopenic purpura 45 nortriptyline 45 haematologic 45 antiestrogen therapy 45 carcinoma mCRC 45 antiretroviral therapy 45 chemotherapy treatments 45 metastasized breast cancer 45 anti angiogenic therapy 45 untreated de novo 45 drug DMARD 45 6 mercaptopurine 45 unipolar depression 45 autoantibody positive 45 Acute Myeloid Leukaemia 45 cell lymphoma ALCL 45 sunitinib Sutent ® 45 Epratuzumab 45 diagnosed GBM 45 motesanib 45 interferon alfa 45 ulcerative colitis UC 45 Dacogen injection 45 Pharmacokinetics PK 45 regorafenib 45 metastatic disease 45 paclitaxel carboplatin 45 relapsed acute lymphoblastic 45 antiviral therapy 45 experienced virologic failure 45 allogeneic stem cell 45 pediatric malignancies 45 mg/m2/day 45 rituximab refractory follicular 45 CAELYX 45 chemotherapy cisplatin 45 divalproex 45 chronic GVHD 45 sustained virological response 45 receiving highly emetogenic 45 adverse cytogenetics 45 Ph + CML 45 null responder HCV 45 Phase 1b trial 45 antipsychotic medications 45 OHR/AVR# 45 Phase 1b 45 Chronic Myelogenous Leukemia CML 45 goserelin 45 FOLPI regimen 45 diagnosed 45 Ceflatonin 45 cyclophosphamide methotrexate 45 subcutaneous enoxaparin 45 REVLIMID lenalidomide 45 Toxicities 45 opioid dependence 45 HBeAg negative 45 receiving VICTRELIS 45 dose escalation 45 CYT# potent vascular disrupting 45 YONDELIS 45 Phase 2a 45 antiretroviral naïve 45 metastatic bladder 45 romiplostim 45 opioid dependent 45 dosed orally 45 unresectable Stage III 45 chemoradiation therapy 45 Paxil paroxetine 45 COU AA 45 FluCAM 45 hepatocellular carcinoma HCC 45 rhTSH 45 REOLYSIN ® 45 acute promyelocytic leukemia 45 IV malignant melanoma 45 splenectomized patients 45 acute manic 45 abatacept Orencia 45 recurrent genital herpes 45 divalproex sodium 45 Refractory Hodgkin Lymphoma 45 placebo controlled clinical trials 45 telaprevir dosing 45 anaplastic astrocytoma 45 prospectively defined 45 oral clodronate 45 plus gemcitabine 45 refractory metastatic 45 ZOLINZA 45 EOquin TM 45 pegylated interferon alpha 2a 45 MAGE A3 ASCI 45 unresectable recurrent 45 Ph + CP 45 Phase IIa clinical 45 celgosivir 45 neoadjuvant therapy 45 HER2 + 45 Myelofibrosis 45 Mantle Cell Lymphoma 45 Solid Tumors criteria 45 Philadelphia Chromosome Positive 45 velaglucerase alfa 45 arsenic trioxide 45 Genasense 45 Ribavirin 45 etanercept 45 antiangiogenic therapy 45 cediranib 45 Velcade bortezomib 45 stem cell transplant 45 Vidaza azacitidine 45 opioid induced constipation OIC 45 uric acid lowering 45 bevacizumab Avastin 45 indolent follicular non 45 abatacept 45 myelogenous leukemia 45 Campral 45 autologous stem cell 45 brain tumor glioblastoma multiforme 45 LEXIVA r 45 Zevalin 45 risperidone Risperdal 45 infusional 5-FU/LV 45 mg m² 45 oblimersen 45 administered subcutaneously 45 efavirenz EFV 45 neoadjuvant treatment 45 QD dosing 45 IIa trial 45 erlotinib Tarceva 45 hormone receptor positive 45 Phase Ib 45 tiotropium 45 Omnitarg 45 castrate resistant prostate cancer 45 Vivitrol 45 nephrotic syndrome 45 #mg QD [002] 45 mcg albinterferon alfa 2b 45 lopinavir r 45 MGd 45 hypercalcemia 45 febrile neutropenia 45 anti TNF alpha 45 juvenile myelomonocytic leukemia 45 EGFR mutation positive 45 chronic HCV genotype 45 TREANDA 45 immunomodulatory therapy 45 PNP inhibitor 45 iclaprim 45 Gemzar ® 45 achieved PASI 45 NOXAFIL Oral Suspension 45 phase IIb study 44 imetelstat 44 placebo intravenously 44 chemotherapies 44 active comparator 44 Vidaza 44 PKC# 44 Phase IIa 44 HGS# 44 PegIntron 44 gemcitabine Gemzar ® 44 Ph + 44 olmesartan 44 lamivudine monotherapy 44 dexanabinol 44 Free Survival PFS 44 peginterferon alpha 2a 44 Bortezomib 44 Phase IIb trials 44 dose escalation trial 44 unique alkylating agent 44 imatinib mesylate Gleevec 44 rufinamide 44 Tamibarotene 44 HbA1c levels 44 oral antidiabetic agents 44 voreloxin 44 IIa clinical trial 44 VEGF receptor inhibitor 44 class mGluR5 inhibitor 44 docetaxel Taxotere R 44 severe oral mucositis 44 Leukemia AML 44 brentuximab vedotin 44 duodenal ulcer 44 randomized #:#:# 44 drug addiction 44 riociguat 44 velafermin 44 grade glioma 44 drugs DMARDs 44 relapse prevention 44 neuroleptics 44 virologic response 44 Newly Diagnosed Multiple Myeloma 44 RoACTEMRA 44 CRu

Back to home page